Mimotopes
Melbourne, Australia· Est.
A peptide‑mimotope platform company creates targeted vaccines and diagnostics for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A peptide‑mimotope platform company creates targeted vaccines and diagnostics for oncology and immunology.
OncologyImmunology
Technology Platform
High‑throughput phage‑display peptide libraries combined with next‑generation sequencing and bioinformatic epitope mapping to generate conformational mimotopes for vaccines, antibodies and diagnostics.
Opportunities
Successful early‑phase data could unlock multi‑billion‑dollar partnerships and enable rapid expansion into infectious‑disease vaccines.
Risk Factors
Clinical failure, manufacturing scale‑up challenges, and intense competition from mRNA and other peptide vaccine platforms pose significant risks.
Competitive Landscape
Key competitors include Moderna, BioNTech, and peptide‑focused firms like Immunocore; Mimotopes differentiates through its mimotope platform that delivers conformational epitope fidelity and faster development timelines.